Targeting Heat Shock Proteins in Prostate Cancer

$63.00 plus tax (Refund Policy)

Buy Article:


Heat shock proteins (HSPs) and chaperones are highly conserved stress-induced factors. They regulate not only protein folding and stability but are also actively involved in protein transport and transcriptional regulation. HSPs have cytoprotective roles and are essential for cancer cell survival. Noteworthy, HSPs are often upregulated in cancer. Therefore, HSPs emerged as drug targets for cancer therapy. Especially for prostate cancer (PCa) therapy, a battery of different compounds has been identified that act with different modes to inhibit PCa growth. The androgen receptor (AR) is a major player in PCa progression and is a well-known interacting factor of HSPs. Since the AR function is very dependent on HSP activity, many emerging compounds address the AR-associated HSPs as novel drug targets. Here, we provide an insight into the different classes of HSPs, their association with the human AR, the role of HSPs in human PCa development and review also the targeting of HSPs in human PCa. Further, the function and the underlying molecular mechanisms of specific compounds that are currently under investigation for the use against PCa growth will be comprehensively summarized.

Keywords: Androgen receptor; chaperones; heat shock proteins; prostate cancer therapy

Document Type: Research Article

Publication date: July 1, 2013

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
Related content



Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more